甲状腺髓样癌患者术前与术后循环肿瘤DNA检测
本研究评估散发性甲状腺髓样癌(sMTC)患者术前与术后循环肿瘤DNA(ctDNA)的临床相关性,分别检测26例和23例患者。术前ctDNA阳性与RET M918T突变、更高的体细胞驱动突变变异等位基因频率及持续性疾病相关;术后ctDNA阳性仅见于3/23例,且7例术前或术后ctDNA阳性患者均存在持续性疾病。作者认为术前ctDNA不用于诊断但可能预测结局,术后ctDNA有监测治疗反应的潜力,需进一步研究证实。
要点
- 26例sMTC中4例(15.4%)术前ctDNA阳性,与RET M918T突变显著相关(P=0.0468)。
- 术前ctDNA阳性患者持续性疾病频率更高(P=0.0221)。
- 7例术前或术后ctDNA阳性患者均存在持续性疾病(P=0.0005)。
核心结论
- 术前ctDNA在甲状腺髓样癌中不用于诊断目的,但可能有助于预测疾病结局。
- 在本系列中,术后ctDNA显示出监测治疗反应的潜力,但需进一步研究证实。
研究设计与样本
- 研究纳入26例和23例散发性甲状腺髓样癌(sMTC)患者,分别检测术前和术后ctDNA。
- 将ctDNA结果与血清降钙素(Ct)、癌胚抗原(CEA)及其他临床/病理特征进行相关性分析。
主要发现
- 29例sMTC中26例(89.7%)存在RET或RAS突变,3例(10.3%)为阴性。
- 26例术前ctDNA检测中4例(15.4%)阳性,阳性者RET M918T突变 presence 显著更高(P=0.0468)。
- 术前ctDNA阳性患者体细胞驱动突变变异等位基因频率值更高(P=0.0434),持续性疾病频率更高(P=0.0221)。
- 术后ctDNA仅3/23例(13%)阳性,且无一例术前ctDNA阳性。
- ctDNA阳性病例中Ct(P=0.0307)和CEA(P=0.0013)值均更高。
临床怎么用
- 作者认为术前ctDNA不用于诊断目的,但可能有助于预测疾病结局。
- 作者认为术后ctDNA显示出监测治疗反应的潜力,但需进一步研究证实。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Measurement of driver mutations in circulating tumoral DNA (ctDNA) obtained by liquid biopsy has been shown to be a sensitive biomarker in several human tumors. OBJECTIVE: The aim of this study was to evaluate the clinical relevance of pre- and post-operative ctDNA in sporadic medullary thyroid cancer (sMTC). METHODS: We studied pre- and post-operative ctDNA in 26 and 23 sMTC patients, respectively. ctDNA results were correlated to serum calcitonin (Ct), carcinoembryonic antigen (CEA), and other clinical/pathological features. RESULTS: Twenty-six of 29 (89.7%) sMTCs were mutated either for RET or RAS and 3/29 (10.3%) were negative. Four of 26 (15.4%) cases showed positive pre-operative ctDNA with a significantly higher presence of RET M918T mutation (P = 0.0468). Patients with positive pre-operative ctDNA showed a higher variation allele frequency value of the somatic driver mutation (P = 0.0434) and a higher frequency of persistent disease (P = 0.0221). Post-operative ctDNA was positive only in 3/23 (13%) sMTCs and no one was positive for pre-operative ctDNA. Higher values of both Ct (P = 0.0307) and CEA (P = 0.0013) were found in positive ctDNA cases. Finally, the 7 cases harboring either pre- or post-operative positive ctDNA had a persistent disease (P = 0.0005) showing a higher post-operative serum Ct when compared with cases with negative ctDNA (P = 0.0092). CONCLUSIONS: Pre-operative ctDNA in medullary thyroid cancer is not useful for diagnostic purposes, but it can be useful for predicting the outcome of the disease. In our series, post-operative ctDNA showed a potential for monitoring the response to therapies, but further studies are required to confirm our results.
引用
- Ciampi R, Romei C, Ramone T, et al. Pre- and Post-operative Circulating Tumoral DNA in Patients With Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2022. PMID: 35470851. doi:10.1210/clinem/dgac222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。